Arax Advisory Partners’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.2M | Buy |
50,310
+45,081
| +862% | +$15.4M | 0.12% | 182 |
|
|
2026
Q1 | $1.84M | Sell |
5,229
-481
| -8% | -$171K | 0.05% | 293 |
|
|
2025
Q4 | $1.87M | Buy |
5,710
+2,676
| +88% | +$849K | 0.05% | 248 |
|
|
2025
Q3 | $856K | Buy |
3,034
+2,014
| +197% | +$584K | 0.01% | 706 |
|
|
2025
Q2 | $863K | Sell |
1,020
-803
| -44% | -$227K | 0.04% | 272 |
|
|
2025
Q1 | $568K | Sell |
1,823
-463
| -20% | -$137K | 0.04% | 280 |
|
|
2024
Q4 | $596K | Buy |
2,286
+1,574
| +221% | +$467K | 0.04% | 252 |
|
|
2024
Q3 | $229K | Buy |
712
+14
| +2% | +$4.58K | 0.02% | 322 |
|
|
2024
Q2 | $218K | Buy |
698
+592
| +558% | +$174K | 0.02% | 313 |
|
|
2024
Q1 | $30.1K | Buy |
106
+1
| +1% | +$293 | ﹤0.01% | 593 |
|
|
2023
Q4 | $30.4K | Sell |
105
-1
| -0.9% | -$272 | ﹤0.01% | 574 |
|
|
2023
Q3 | $28.6K | Buy |
106
+11
| +12% | +$2.75K | ﹤0.01% | 540 |
|
|
2023
Q2 | $21.1K | Sell |
95
-10
| -10% | -$2.32K | ﹤0.01% | 576 |
|
|
2023
Q1 | $25.4K | Buy |
105
+24
| +30% | +$5.89K | ﹤0.01% | 547 |
|
|
2022
Q4 | $21.3K | Sell |
81
-2
| -2% | -$536 | ﹤0.01% | 550 |
|
|
2022
Q3 | $19K | Sell |
83
-4,448
| -98% | -$1.08M | ﹤0.01% | 573 |
|
|
2022
Q2 | $1.1M | Buy |
4,531
+4
| +0.1% | +$980 | 0.17% | 65 |
|
|
2022
Q1 | $1.09M | Buy |
4,527
+9
| +0.2% | +$2.07K | 0.15% | 71 |
|
|
2021
Q4 | $1.02M | Sell |
4,518
-241
| -5% | -$50.9K | 0.13% | 73 |
|
|
2021
Q3 | $1.01M | Buy |
4,759
+119
| +3% | +$27.4K | 0.14% | 72 |
|
|
2021
Q2 | $1.13M | Buy |
+4,640
| New | +$1.14M | 0.15% | 63 |
|
|
2020
Q4 | $1.06M | Sell |
4,624
-120
| -3% | -$27.7K | 0.16% | 54 |
|
|
2020
Q3 | $1.21M | Sell |
4,744
-941
| -17% | -$233K | 0.2% | 51 |
|
|
2020
Q2 | $1.34M | Sell |
5,685
-213
| -4% | -$48.6K | 0.24% | 50 |
|
|
2020
Q1 | $1.2M | Sell |
5,898
-33
| -0.6% | -$7.21K | 0.28% | 48 |
|
|
2019
Q4 | $1.43M | Buy |
5,931
+4,792
| +421% | +$1.06M | 0.41% | 29 |
|
|
2019
Q3 | $220K | Buy |
1,139
+3
| +0.3% | +$576 | 0.07% | 135 |
|
|
2019
Q2 | $209K | Buy |
+1,136
| New | +$203K | 0.07% | 136 |
|
|
2018
Q4 | $423K | Buy |
2,175
+399
| +22% | +$77.8K | 0.17% | 68 |
|
|
2018
Q3 | $368K | Sell |
1,776
-615
| -26% | -$121K | 0.15% | 79 |
|
|
2018
Q2 | $441K | Buy |
2,391
+420
| +21% | +$74.3K | 0.19% | 53 |
|
|
2018
Q1 | $336K | Sell |
1,971
-78
| -4% | -$14.3K | 0.17% | 57 |
|
|
2017
Q4 | $356K | Buy |
2,049
+58
| +3% | +$10.3K | 0.15% | 58 |
|
|
2017
Q3 | $371K | Sell |
1,991
-317
| -14% | -$56.2K | 0.18% | 47 |
|
|
2017
Q2 | $395K | Buy |
2,308
+612
| +36% | +$99.5K | 0.19% | 47 |
|
|
2017
Q1 | $278K | Buy |
1,696
+316
| +23% | +$52.5K | 0.13% | 55 |
|
|
2016
Q4 | $202K | Buy |
+1,380
| New | +$208K | 0.1% | 58 |
|
Other funds holding AMGN
Arax Advisory Partners's AMGN Position: Q2 2026 in Review
Arax Advisory Partners increased its Amgen (AMGN) stake by 862% in Q2 2026, buying an estimated $15.4M and bringing the position to 50,310 shares worth $18.2M. The position accounts for 0.12% of the portfolio, ranked #182.
Arax Advisory Partners first reported a position in AMGN in Q4 2016 and has held it in 37 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Arax Advisory Partners held 50,310 shares of Amgen worth $18.2M as of Q2 2026.
- Arax Advisory Partners bought 45,081 Amgen shares in Q2 2026, an estimated $15.4M.
- Amgen made up 0.12% of Arax Advisory Partners's portfolio in Q2 2026, its #182 holding.
- Arax Advisory Partners first reported a position in Amgen in Q4 2016 and has held it in 37 quarters since.
- 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.